Appointment of Two Executives to Support Advancement of Product
Pipeline: Christine Boisclair Named Vice President, Regulatory Affairs,
and Scott Weintraub Named Vice President, Commercial and Product Strategy
LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the expansion
of its senior management team with the appointment of executives in
regulatory affairs and commercial strategy to serve in leadership roles
as the Company advances its clinical pipeline. Christine Boisclair has
been appointed as Vice President, Regulatory Affairs, with primary
responsibility for planning and coordinating Concert's regulatory
submissions to the U.S. Food and Drug Administration (FDA) and other
regulatory authorities. She replaces Mark Roessel, who recently retired
following a long and successful career in the pharmaceutical industry.
Scott Weintraub has joined Concert in the newly created position of Vice
President, Commercial and Product Strategy, with responsibilities
including overseeing the Company's commercial strategy and market
assessments for Concert's drug candidates and pipeline.
"We are delighted that Christine and Scott will contribute their
expertise and talents to Concert's success in our next stage of growth
as we continue to advance our product candidates toward approval," said
Roger Tung, Ph.D., President and CEO of Concert Pharmaceuticals, Inc.
"The addition of these outstanding leaders to our management team
reflects the substantial progress we have made to date with our product
candidates for the treatment of cystic fibrosis and alopecia areata."
Christine Boisclair, Vice President, Regulatory Affairs
Boisclair joins Concert with more than 30 years of regulatory affairs
experience in the biopharmaceutical industry across multiple therapeutic
areas. Prior to joining Concert, Ms. Boisclair was Vice President,
Regulatory Affairs, at Forum Pharmaceuticals. Before joining Forum
Pharmaceuticals, she held management roles at several companies
including Insmed, Agennix, OSI Pharmaceuticals, Genzyme Corporation,
Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair also
worked in regulatory at Searle Pharmaceuticals and Glaxo in the U.K. She
received a Bachelor of Science Honors Degree in Biochemistry from the
University of York in the U.K.
Scott Weintraub, Vice President, Commercial and Product Strategy
Weintraub joins Concert with more than 17 years of commercial experience
in the biopharmaceutical industry, including strategic product
assessment, brand positioning, commercial life cycle management, and
sales and marketing. Prior to joining Concert, he was Vice President of
Product Strategy and Marketing at Forum Pharmaceuticals. He also served
as Senior Director of Marketing at Sunovion Pharmaceuticals and held
sales and marketing positions at AstraZeneca. He holds a B.S. in Finance
and Marketing from Florida State University and an M.B.A. in Health
Administration and Policy from University of Miami.
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, central nervous systems (CNS) disorders, as
well as autoimmune and inflammatory diseases. For more information
please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005210/en/
Concert Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media